期刊
JOURNAL OF FUNCTIONAL BIOMATERIALS
卷 3, 期 1, 页码 79-99出版社
MDPI
DOI: 10.3390/jfb3010079
关键词
PLGA; alendronate; bone-seeking polymer; nanoparticles; biocompatibility; hemocompatibility; doxorubicin; osteolytic tumors; bone metastasis
资金
- Associazione Italiana per la Ricerca sul Cancro (AIRC)
Bone-seeking (osteotropic) drug delivery systems (ODDS) represent an interesting solution for targeting different types of drugs to the bones. In particular, anticancer and antibacterial agents could take advantage of such therapeutic strategy. We have recently developed an innovative approach to this aim: a new osteotropic biomaterial was prepared, based on the conjugation of a poly(lactide-co-glycolide) (PLGA) with the bisphosphonate drug alendronate (PLGA-ALE); its hemo-and cytocompatibility were verified. Starting with this copolymer, an osteotropic nanoparticle system (NP) was produced for the targeted delivery of antineoplastic drugs to osteolytic bone metastases; in particular, doxorubicin was tested as a model drug. The in vitro and in vivo results of the new ODDS are validated in this article. All the experimental data confirmed that the drug retained its activity after loading in the PLGA-ALE NP; they can be thus considered a new promising strategy for active targeting of drugs to bone tissues in different pathological situations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据